Yozma

An AI-powered chatbot for hotels revolutionizes the way guests interact with in-room services by enabling seamless cross-selling and upselling. Integrated within smart devices or hotel apps, this AI solution leverages natural language processing (NLP) to communicate with guests in a conversational and personalized manner. From booking spa treatments and restaurant reservations to upgrading rooms or scheduling late checkouts, the chatbot intuitively identifies guest preferences and suggests relevant services. It analyzes data such as guest profiles, previous stays, and real-time behavior to deliver tailored recommendations, boosting both guest satisfaction and revenue. Available 24/7, the chatbot ensures instant responses to guest inquiries, reducing dependence on front-desk staff and enhancing operational efficiency. Additionally, it supports multiple languages, catering to a global clientele and making communication barrier-free. Hotels can integrate the AI chatbot with their property management systems (PMS) and point-of-sale (POS) platforms to streamline service delivery and track guest interactions. The solution empowers hotels to provide a hyper-personalized, tech-forward experience, which appeals to modern travelers. By automating cross-selling and upselling opportunities while improving guest engagement, the chatbot not only enhances the overall stay experience but also drives incremental revenue, making it a vital tool for the hospitality industry.

Meat.The End is a company focused on developing innovative protein texturizing technologies aimed at transforming plant-based meat alternatives. By utilizing advanced extrusion processing, the company enhances the texture and appearance of plant-based products to closely resemble animal proteins. This technology addresses a significant barrier to consumer adoption of meat substitutes, as the texture of many existing alternatives often falls short of expectations. Meat.The End's solutions enable producers of plant-based proteins to create nutritionally balanced products that offer a more convincing and satisfying eating experience, ultimately facilitating the mass production of healthier alternatives to traditional animal-based foods. Through its industry-oriented approach, the company contributes to the advancement of the plant-based food sector.

Meat.The End is a company focused on developing innovative protein texturizing technologies aimed at transforming plant-based meat alternatives. By utilizing advanced extrusion processing, the company enhances the texture and appearance of plant-based products to closely resemble animal proteins. This technology addresses a significant barrier to consumer adoption of meat substitutes, as the texture of many existing alternatives often falls short of expectations. Meat.The End's solutions enable producers of plant-based proteins to create nutritionally balanced products that offer a more convincing and satisfying eating experience, ultimately facilitating the mass production of healthier alternatives to traditional animal-based foods. Through its industry-oriented approach, the company contributes to the advancement of the plant-based food sector.

Fine Data Lab is a digital data analysis company that specializes in providing advanced analytics and data modeling services. It offers a comprehensive range of solutions, including digital marketing consulting, data integration, and visualization services. By leveraging its data analysis platform, Fine Data Lab helps businesses make informed decisions and gain a competitive edge through actionable insights derived from data. The company's focus on delivering tailored analytics services enables clients to effectively harness the power of data for strategic growth and performance enhancement.

Illumigyn is a medical technology company that specializes in developing advanced imaging solutions for cervical cancer examinations. Its flagship product, the Gynescope, is a patented compact imaging colposcope that offers 15-micron image resolution and features multispectral illumination options. This innovative technology aims to minimize the subjectivity associated with traditional cervical exams, thereby enhancing the accuracy of diagnoses. The Gynescope allows for sophisticated imaging capabilities while enabling simultaneous complex interventional procedures, ultimately supporting improved clinical outcomes in women's health. By incorporating existing machine vision technologies into a user-friendly format, Illumigyn strives to facilitate early detection of cervical cancer and reduce the likelihood of misdiagnoses.

OP.GG is an e-gaming data analytics company that focuses on enhancing the gaming experience for players by creating detailed profiles based on their gameplay data. The platform supports popular games such as League of Legends, Overwatch, and PUBG, enabling users to analyze their own performance as well as that of their opponents and friends. With a user base exceeding 28 million monthly, OP.GG provides valuable insights that help gamers improve their skills and navigate the competitive landscape more effectively. The company's mission is to foster a better gaming ecosystem by equipping players with the tools they need to succeed.

UltraSight is a company focused on transforming cardiac ultrasound through machine learning technology. Its automated guidance system enhances the quality and accessibility of cardiac care by assisting ultrasound operators in capturing high-quality images efficiently. This innovative approach allows healthcare professionals to perform cardiac imaging in diverse settings, thereby facilitating timely diagnoses and treatments for heart disease. UltraSight's contributions to the field were recognized when it won the TCT 2020 Innovation Competition at the Transcatheter Cardiovascular Therapeutics world conference. Through its advancements, UltraSight aims to ensure that patients can receive essential ultrasound services in a wider range of environments.

Todos Medical Ltd is an in vitro diagnostics company specializing in the development of innovative testing solutions for various health conditions, including breast cancer, Alzheimer's disease, and COVID-19. The company leverages a multidisciplinary team with expertise in medicine, physics, biochemistry, digital signal processing, and electrical engineering, which provides a competitive edge in the diagnostics field. Todos Medical generates all of its revenue from the United States, focusing on advancing healthcare through its specialized testing services.

Nanox Imaging is a Gibraltar-based company founded in 2011 that specializes in advanced imaging technology for medical, security, and telecommunications applications. The company is pioneering next-generation X-ray emitters utilizing innovative nanotechnology to modernize X-ray imaging, enabling the development of novel 3D imaging systems with superior performance. Central to Nanox's offerings is the Nanox System, which provides a preventative healthcare service known as Medical Screening As A Service (MSaaS). The company has leveraged over two decades of research and development, investing more than $1 billion to create proprietary cold cathode technology that enhances X-ray imaging capabilities. This technology features a chip composed of nano-scale structures, designed through unique nanofabrication techniques, which supports various medical imaging applications and is complemented by additional technologies to maximize its practical benefits in real-world scenarios.

UltraSight is a company focused on transforming cardiac ultrasound through machine learning technology. Its automated guidance system enhances the quality and accessibility of cardiac care by assisting ultrasound operators in capturing high-quality images efficiently. This innovative approach allows healthcare professionals to perform cardiac imaging in diverse settings, thereby facilitating timely diagnoses and treatments for heart disease. UltraSight's contributions to the field were recognized when it won the TCT 2020 Innovation Competition at the Transcatheter Cardiovascular Therapeutics world conference. Through its advancements, UltraSight aims to ensure that patients can receive essential ultrasound services in a wider range of environments.

BiSiChem is a biotechnology company dedicated to drug discovery and development, particularly in the fields of immuno-oncology and central nervous system therapies. The company concentrates on identifying molecular drug targets to create innovative anti-cancer treatments and immunosuppressive medications. Additionally, BiSiChem is engaged in the research and development of new therapeutics aimed at Alzheimer's disease, striving to provide first-in-class treatment options for patients facing these challenging health issues.

NextNine Ltd. is a developer of operational technology security management software, specializing in solutions for industrial and critical infrastructure sectors. Founded in 1998 and based in New York, the company offers a comprehensive platform that enables centralized security management for SCADA and ICS environments, addressing the unique vulnerabilities of these systems to cyber security threats. NextNine's software is designed to protect multi-site remote field assets and facilitate remote maintenance and support, which are critical in industries such as oil, gas, mining, chemicals, energy, manufacturing, and defense. The company has established itself as a leader in the OT security space, with over 6,000 installations globally and recognition for its contributions to improving critical infrastructure cyber security. NextNine has received ISO/IEC 27001:2013 certification, demonstrating its commitment to managing information security risks effectively. Formerly known as RTview Ltd., the company has been a subsidiary of Honeywell International Inc. since 2017.

Kailight Photonics develops optical modules for the telecommunications industry. It offers tunable optical signal regenerator, an optical component that operates with regenerators, optical switches, add/drop multiplexers, and cross-connects. The company's optical transmission, signal regeneration, and wavelength conversion technology provides optical-networking solutions for systems vendors. It provides its products to long-haul network market segments. The company, formerly known as Chilight Technologies, was founded in 2000 and is headquartered in Rehovot, Israel with an additional office in Dallas, Texas. As of May 15, 2007, Kailight Photonics, Inc. operates as a subsidiary of Optium Corporation.

CogniTens, Ltd. specializes in three-dimensional optical measurement solutions aimed at enhancing manufacturing processes, particularly in the automotive sector. The company offers a range of products, including Optigo, a portable measurement platform for direct use by operators and engineers, and OptiCell, an automated system for off-line recurring measurements of parts and assemblies. Additionally, CogniTens provides comprehensive software solutions such as CoreView Plan for planning measurement programs, CoreView Pro for analyzing and reporting data, and CoreView Lite for viewing measurement results. These systems are designed to support various industrial engineering activities, including tooling, part production, assembly, and quality control. Established in 1995 and headquartered in Ramat Hasharon, Israel, CogniTens serves a wide array of clients, including automotive OEMs, tier-1 suppliers, and tool and die companies, with a global presence that includes offices across North America, South America, Europe, and Asia.

Predix Pharmaceuticals Holdings is a drug discovery and development company specializing in small-molecule drugs targeting G-protein coupled receptors (GPCRs) and ion channels. The company employs an innovative 3D Discovery and Optimization Engine, which includes its proprietary PREDICT algorithm for modeling the 3D structure of GPCR targets. Additionally, Predix utilizes advanced technologies such as HYPERION and RISS for high-throughput in silico screening of millions of compounds against these models. Its integrated medicinal and computational platform, ICELR-3D, aids in lead optimization by employing predictive algorithms for crucial drug properties. Predix's research focuses on developing treatments for various conditions, including anxiety, Alzheimer's disease, and pulmonary arterial hypertension. In a strategic move to enhance its capabilities, Predix merged with Physiome Sciences Inc., thereby expanding its expertise into ion channel drug discovery.

NextNine Ltd. is a developer of operational technology security management software, specializing in solutions for industrial and critical infrastructure sectors. Founded in 1998 and based in New York, the company offers a comprehensive platform that enables centralized security management for SCADA and ICS environments, addressing the unique vulnerabilities of these systems to cyber security threats. NextNine's software is designed to protect multi-site remote field assets and facilitate remote maintenance and support, which are critical in industries such as oil, gas, mining, chemicals, energy, manufacturing, and defense. The company has established itself as a leader in the OT security space, with over 6,000 installations globally and recognition for its contributions to improving critical infrastructure cyber security. NextNine has received ISO/IEC 27001:2013 certification, demonstrating its commitment to managing information security risks effectively. Formerly known as RTview Ltd., the company has been a subsidiary of Honeywell International Inc. since 2017.

CogniTens, Ltd. specializes in three-dimensional optical measurement solutions aimed at enhancing manufacturing processes, particularly in the automotive sector. The company offers a range of products, including Optigo, a portable measurement platform for direct use by operators and engineers, and OptiCell, an automated system for off-line recurring measurements of parts and assemblies. Additionally, CogniTens provides comprehensive software solutions such as CoreView Plan for planning measurement programs, CoreView Pro for analyzing and reporting data, and CoreView Lite for viewing measurement results. These systems are designed to support various industrial engineering activities, including tooling, part production, assembly, and quality control. Established in 1995 and headquartered in Ramat Hasharon, Israel, CogniTens serves a wide array of clients, including automotive OEMs, tier-1 suppliers, and tool and die companies, with a global presence that includes offices across North America, South America, Europe, and Asia.

Can-Fite BioPharma is an Israeli biopharmaceutical company engaged in the discovery and clinical development of therapeutics for cancer and inflammatory diseases. The company specializes in developing orally bioavailable small molecule drugs that target the A3 adenosine receptor (A3AR). Can-Fite's lead drug candidate, Piclidenoson, is currently in a Phase III trial aimed at treating psoriasis. Additionally, Namodenoson, another key product, is advancing into a Phase III trial for hepatocellular carcinoma, the most prevalent form of liver cancer, and is also undergoing a Phase IIb trial for non-alcoholic steatohepatitis. With a robust pipeline of proprietary compounds in advanced clinical stages, Can-Fite is focused on addressing significant unmet medical needs in autoimmune-inflammatory conditions and cancer.

Predix Pharmaceuticals Holdings is a drug discovery and development company specializing in small-molecule drugs targeting G-protein coupled receptors (GPCRs) and ion channels. The company employs an innovative 3D Discovery and Optimization Engine, which includes its proprietary PREDICT algorithm for modeling the 3D structure of GPCR targets. Additionally, Predix utilizes advanced technologies such as HYPERION and RISS for high-throughput in silico screening of millions of compounds against these models. Its integrated medicinal and computational platform, ICELR-3D, aids in lead optimization by employing predictive algorithms for crucial drug properties. Predix's research focuses on developing treatments for various conditions, including anxiety, Alzheimer's disease, and pulmonary arterial hypertension. In a strategic move to enhance its capabilities, Predix merged with Physiome Sciences Inc., thereby expanding its expertise into ion channel drug discovery.

HyWire Ltd., established in 1999 and headquartered in Netanya, Israel, specializes in the development, manufacturing, and marketing of silicon-based search and classification VLSI components and subsystems. The company's products cater to high-end switching and routing equipment, addressing the growing demand for high-speed and high-capacity Internet services. As bandwidth requirements surge due to increased user activity and the proliferation of network applications such as video streaming, voice over IP, and e-commerce, HyWire is positioned to provide essential solutions that meet these technological needs.

NextNine Ltd. is a developer of operational technology security management software, specializing in solutions for industrial and critical infrastructure sectors. Founded in 1998 and based in New York, the company offers a comprehensive platform that enables centralized security management for SCADA and ICS environments, addressing the unique vulnerabilities of these systems to cyber security threats. NextNine's software is designed to protect multi-site remote field assets and facilitate remote maintenance and support, which are critical in industries such as oil, gas, mining, chemicals, energy, manufacturing, and defense. The company has established itself as a leader in the OT security space, with over 6,000 installations globally and recognition for its contributions to improving critical infrastructure cyber security. NextNine has received ISO/IEC 27001:2013 certification, demonstrating its commitment to managing information security risks effectively. Formerly known as RTview Ltd., the company has been a subsidiary of Honeywell International Inc. since 2017.

Predix Pharmaceuticals Holdings is a drug discovery and development company specializing in small-molecule drugs targeting G-protein coupled receptors (GPCRs) and ion channels. The company employs an innovative 3D Discovery and Optimization Engine, which includes its proprietary PREDICT algorithm for modeling the 3D structure of GPCR targets. Additionally, Predix utilizes advanced technologies such as HYPERION and RISS for high-throughput in silico screening of millions of compounds against these models. Its integrated medicinal and computational platform, ICELR-3D, aids in lead optimization by employing predictive algorithms for crucial drug properties. Predix's research focuses on developing treatments for various conditions, including anxiety, Alzheimer's disease, and pulmonary arterial hypertension. In a strategic move to enhance its capabilities, Predix merged with Physiome Sciences Inc., thereby expanding its expertise into ion channel drug discovery.

Globecom Interactive Commerce, Inc. is a U.S.-Israel company that specializes in broadband-enabled solutions for the presentation of products and services. Founded in 1998 and headquartered in Chantilly, Virginia, with research and development facilities in Herzliya, Israel, the company focuses on developing enterprise-grade, end-to-end broadband solutions. These solutions facilitate the creation, management, and delivery of rich dynamic media across various platforms, enabling businesses to enhance the productivity of both new and established Internet market channels.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It specializes in the research, development, and commercialization of novel therapeutic candidates primarily in the field of cancer immunotherapy. The company's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT, both designed for the treatment of solid tumors. Compugen employs advanced computational methods for drug discovery, utilizing in silico techniques to predict and select promising drug targets, followed by rigorous experimental validation. The company collaborates with major pharmaceutical partners, including Bayer Pharma AG and Bristol-Myers Squibb, to enhance its research and development efforts. Compugen's focus on innovative therapeutic solutions aims to address significant unmet medical needs in oncology, leveraging its unique predictive capabilities and a robust pipeline of early-stage programs targeting immune resistance mechanisms.

Cardonet is a provider of IT support and technology services, dedicated to maximizing revenue and supporting business growth. Founded in 1999, the company offers a comprehensive range of managed IT services, including assistance with forgotten passwords, server emergencies, office relocations, and data center design. Cardonet's commitment to ensuring smooth IT operations is evident in its hands-on approach, with directors often directly engaging with clients to deliver solutions. The company also enables e-marketplaces to create and maintain transactive catalogs, enhancing the buyer's experience and increasing marketplace transactions. Through its focus on effective technology use, Cardonet aims to help businesses gain a competitive advantage in their respective industries.

HarmonyCom is a privately held, venture-backed telecommunications software solutions provider founded in 1997. It has its U.S. headquarters in Ann Arbor, Michigan with operations in London and Tel Aviv. The lead investor in HarmonyCom is Iscal Holdings, Ltd., a private Israeli investment company that focuses on emerging high-tech companies. Additional funding has been received from Yozma Venture Capital. HarmonyCom's premier product is Harmony, a software solution that automates and orchestrates the delivery of broadband data services, allowing for measurable improvements in customer satisfaction, faster time-to-market for new products, reduced operational costs, and improved accuracy of information.

Telegate is a developer of the most reliable and feature-rich VoIP system.

NextNine Ltd. is a developer of operational technology security management software, specializing in solutions for industrial and critical infrastructure sectors. Founded in 1998 and based in New York, the company offers a comprehensive platform that enables centralized security management for SCADA and ICS environments, addressing the unique vulnerabilities of these systems to cyber security threats. NextNine's software is designed to protect multi-site remote field assets and facilitate remote maintenance and support, which are critical in industries such as oil, gas, mining, chemicals, energy, manufacturing, and defense. The company has established itself as a leader in the OT security space, with over 6,000 installations globally and recognition for its contributions to improving critical infrastructure cyber security. NextNine has received ISO/IEC 27001:2013 certification, demonstrating its commitment to managing information security risks effectively. Formerly known as RTview Ltd., the company has been a subsidiary of Honeywell International Inc. since 2017.